BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 38504071)

  • 1. Current status of neoadjuvant immunotherapy for the treatment of gastric cancer.
    Zhang X; Liu B; Wang R; Li X; Zhou W
    Clin Transl Oncol; 2024 Mar; ():. PubMed ID: 38504071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Safety and efficacy of laparoscopic surgery in locally advanced gastric cancer patients with neoadjuvant chemotherapy combined with immunotherapy].
    Lv JB; Yin YP; Zhang P; Cai M; Chen JH; Li W; Li G; Wang Z; Wang GB; Tao KX
    Zhonghua Wei Chang Wai Ke Za Zhi; 2023 Jan; 26(1):84-92. PubMed ID: 36650004
    [No Abstract]   [Full Text] [Related]  

  • 3. Survival and complications after neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for locally advanced gastric cancer: a systematic review and meta-analysis.
    Zhu Y; Chen J; Sun X; Lou Y; Fang M; Zhou F; Zhang L; Xin Y
    Front Oncol; 2023; 13():1177557. PubMed ID: 37228495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Clinical and Safety Outcomes of Neoadjuvant Immunotherapy Combined With Chemotherapy for Patients With Resectable Esophageal Cancer: A Systematic Review and Meta-analysis.
    Ge F; Huo Z; Cai X; Hu Q; Chen W; Lin G; Zhong R; You Z; Wang R; Lu Y; Wang R; Huang Q; Zhang H; Song A; Li C; Wen Y; Jiang Y; Liang H; He J; Liang W; Liu J
    JAMA Netw Open; 2022 Nov; 5(11):e2239778. PubMed ID: 36322089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison between upfront surgery and neoadjuvant chemotherapy in patients with locally advanced gastric cancer: A systematic review.
    Fiflis S; Papakonstantinou M; Giakoustidis A; Christodoulidis G; Louri E; Papadopoulos VN; Giakoustidis D
    World J Gastrointest Surg; 2023 Aug; 15(8):1808-1818. PubMed ID: 37701690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined systemic immune-inflammatory index (SII) and prognostic nutritional index (PNI) predicts chemotherapy response and prognosis in locally advanced gastric cancer patients receiving neoadjuvant chemotherapy with PD-1 antibody sintilimab and XELOX: a prospective study.
    Ding P; Guo H; Sun C; Yang P; Kim NH; Tian Y; Liu Y; Liu P; Li Y; Zhao Q
    BMC Gastroenterol; 2022 Mar; 22(1):121. PubMed ID: 35287591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of neoadjuvant immunotherapy versus routine neoadjuvant therapy for patients with locally advanced esophageal cancer: A systematic review and meta-analysis.
    Qin H; Liu F; Zhang Y; Liang Y; Mi Y; Yu F; Xu H; Li K; Lin C; Li L; Tian Z; Wang L
    Front Immunol; 2023; 14():1108213. PubMed ID: 37033991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Total neoadjuvant therapy for locally advanced gastric cancer and esophagogastric junction adenocarcinoma: study protocol for a prospective, multicenter, single-arm, phase II clinical trial.
    Shi J; Li N; Tang Y; Jiang L; Yang L; Wang S; Song Y; Liu Y; Fang H; Lu N; Qi S; Chen B; Li Z; Liu S; Wang J; Wang W; Zhu S; Yang J; Li Y; Zhao D; Jin J
    BMC Gastroenterol; 2022 Jul; 22(1):359. PubMed ID: 35902798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of neoadjuvant immunotherapy in surgically resectable esophageal cancer: A systematic review and meta-analysis.
    Wang Z; Shao C; Wang Y; Duan H; Pan M; Zhao J; Wang J; Ma Z; Li X; Yan X
    Int J Surg; 2022 Aug; 104():106767. PubMed ID: 35840049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Current status and prospect of perioperative therapy for locally advanced gastric cancer].
    Zhu ZG
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):101-106. PubMed ID: 33508913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy in locally advanced esophageal cancer: A meta-analysis.
    Wang J; Zhang K; Liu T; Song Y; Hua P; Chen S; Li J; Liu Y; Zhao Y
    Front Oncol; 2022; 12():974684. PubMed ID: 36158679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surgical intervention after neoadjuvant therapy in esophageal cancer: a narrative review.
    Ke J; Xie Y; Liang J; Wang M; Lin W
    J Thorac Dis; 2023 Apr; 15(4):2261-2276. PubMed ID: 37197518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant and neoadjuvant therapy for gastric cancer.
    Kelsen DP
    Semin Oncol; 1996 Jun; 23(3):379-89. PubMed ID: 8658222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Neoadjuvant treatment for locally advanced gastric cancer].
    Zhao LL; Zhao DB; Chen YT
    Zhonghua Zhong Liu Za Zhi; 2020 Nov; 42(11):907-911. PubMed ID: 33256300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perioperative or neoadjuvant chemotherapy for locally advanced gastric or gastroesophageal junction cancer: from independent evidence in the West, the East, and Japan to global collaboration.
    Nakayama I; Ohashi M; Nunobe S
    Chin Clin Oncol; 2024 Feb; 13(1):8. PubMed ID: 38453658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognosis after neoadjuvant chemoradiation or chemotherapy for locally advanced gastro-oesophageal junctional adenocarcinoma.
    Vos EL; Carr RA; Hsu M; Nakauchi M; Nobel T; Russo A; Barbetta A; Tan KS; Tang L; Ilson D; Ku GY; Wu AJ; Janjigian YY; Yoon SS; Bains MS; Jones DR; Coit D; Molena D; Strong VE
    Br J Surg; 2021 Nov; 108(11):1332-1340. PubMed ID: 34476473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant therapy strategies for advanced gastric cancer: Current innovations and future challenges.
    Zhu Z; Gong YB; Xu HM
    Chronic Dis Transl Med; 2020 Sep; 6(3):147-157. PubMed ID: 32908968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperthermic intraperitoneal chemotherapy for gastric cancer: a narrative review.
    Chen C; Justo M; Gangi A
    Chin Clin Oncol; 2023 Dec; 12(6):68. PubMed ID: 38195075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Short-term outcome of programmed cell death protein1 (PD-1) antibody combined with total neoadjuvant chemoradiotherapy in the treatment of locally advanced middle-low rectal cancer with high risk factors].
    Li YJ; Zhang L; Dong QS; Cai Y; Zhang YZ; Wang L; Yao YF; Zhang XY; Li ZW; Li YH; Sun YS; Wang WH; Wu AW
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Nov; 24(11):998-1007. PubMed ID: 34823301
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.